The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Venetoclax combination studies showing great promise at ASH 2017
Venetoclax is a BCL-2 inhibitor used in the treatment of chronic lymphocytic lymphoma (CLL), which works through increasing the apoptosis of CLL cells. In this interview, Constantine Tam, MD, FRACP, FRCPA, of the Peter MacCallum Cancer Centre, Melbourne, Australia, discusses studies of venetoclax combination therapies, such as the MURANO trial (NCT02005471), which is showing promising results for the treatment of relapsed CLL with venetoclax and rituximab, as well as effect of the combination of venetoclax and ibrutinib on MRD in CLL patients. This interview was recorded at the American Society of Hematology (ASH) Annual Meeting 2017, held in Atlanta, GA.
